Results 31 to 40 of about 280,575 (305)

Adjuvant chemotherapy in the elderly

Annals of Oncology, 2003
Cancer is predominantly a disease of the elderly: approximately 60% of all tumors and two-thirds of cancer-related deaths occur in those over 65 years of age. This proportion will grow with the expected increase in the size of the older population in the coming decades.
Biganzoli, Laura, Aapro, Matti
openaire   +3 more sources

Factors related to patient propensity to receive adjuvant chemotherapy and outcomes in stage III gastric cancer cases after D2 surgery

Asian Journal of Surgery, 2019
Summary: Background: Radical gastrectomy and extended lymph node (D2) dissection followed by adjuvant chemotherapy is the optimal treatment for patients with stage III gastric cancer in Asian population.
Jen-Shi Chen, Chia-Yen Hung, Keng-Hao Liu, Chun-Yi Tsai, Yung-Chia Kuo, Jun-Te Hsu, Wen-Chi Chou   +6 more
doaj   +1 more source

Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. [PDF]

, 2010
Oral cavity and oropharyngeal cancers are frequently described as part of a group of oral cancers or head and neck cancer. Treatment of oral cavity cancer is generally surgery followed by radiotherapy, whereas oropharyngeal cancers, which are more likely
Clarkson, Jan E.; id_orcid, null The CSROC Expert Panel, Furness, Susan, Glenny, A.M., Oliver, R., Jan E Clarkson, Macluskey, Michaelina; id_orcid, Furness, S, Glenny, Anne-Marie, Macluskey, M., Clarkson, Jan E., The CSROC Expert Panel, CSROC Expert Panel, Chan, Kelvin K.W., Chan, K.K.W., Conway, DI, Clarkson, Jan E, Conway, David I., Glenny, AM, Clarkson, JE, Kelvin KW Chan, Pavitt, S., Worthington, Helen V, CSROC Expert Panel, [Unknown], Michaelina Macluskey, Furness, S., Worthington, Helen V., The CSROC Expert Panel,, Chan, Kelvin K. W., Pavitt, S, Chan, Kelvin KW, Anne-Marie Glenny, Oliver, R, Glenny, Anne Marie; id_orcid, David I Conway, Conway, D.I., Macluskey, Michaelina, Worthington, HV; id_orcid, Clarkson, J.E., Pavitt, Sue, Chan, KK, Worthington, HV, Macluskey, M, Worthington, Helen V.; id_orcid, Richard Oliver, Oliver, Richard, Helen V Worthington, Susan Furness, Sue Pavitt, Paul Brocklehurst, Worthington, H.V., Brocklehurst, Paul, Brocklehurst, P   +52 more
core   +1 more source

Diabetes alone should not be a reason for withholding adjuvant chemotherapy for stage III colon cancer

, 2011
Background: With increasing prevalence of diabetes mellitus and colon cancer, the number of patients suffering from both diseases is growing, and physicians are being faced with complicated treatment decisions.
Wouter M. W. Dercksen, Extermann, Martine, Harm R. Haak, Janssen-Heijnen, Maryska L.G., van de Schans, Saskia A.M., Haak, Harm R., Dercksen, Wouter M.W., Maren A. van Waalwijk, Martine Extermann, van Waalwijk, Maren A., Saskia A. M. van de Schans, Maryska L. G. Janssen-Heijnen   +11 more
core   +1 more source

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy : results from the BIG 02-98 phase III trial [PDF]

, 2012
Introduction: Pre-clinical data suggest p53-dependent anthracycline-induced apoptosis and p53-independent taxane activity. However, dedicated clinical research has not defined a predictive role for TP53 gene mutations. The aim of the current study was to
Emmanuel Quinaux, Prudence A Francis, Lynnette Fernández-Cuesta, Dell'Orto, P, P. Falagan Lotsch, C. Oakman, A. D. Leo, Pierre Hainaut, Hainaut, P, Azambuja, Evandro De, P. A. Francis, Magali Olivier, D. Larsimont, Larsimont, D, E. Quinaux, G. Viale, Dolci, M Stella, M. S. Dolci, Martine Piccart-Gebhart, Francis, Prudence A, Oakman, C, Dell'orto, Patrizia, Viale, Giuseppe, Evandro De Azambuja, Priscila Falagan-Lotsch, Olivier, Magali, Crown, John, L. Fernández Cuesta, Ke-seay Smoth, Hainaut, Pierre, John Crown, Fernández-Cuesta, L, Viale, G, Leo, Angelo, Larsimont, Denis, M. Piccart Gebhart, Fernández-Cuesta, Lynnette, de Azambuja, Evandro, Giuseppe Viale, Falagan-Lotsch, P, Crown, J, Patrizia Dell'Orto, Piccart-Gebhart, Martine, M Stella Dolci, Piccart-Gebhart, M, Buyse, Marc, Quinaux, E, Denis Larsimont, M. Olivier, M. Buyse, Catherine Oakman, Quinaux, Emmanuel, P. Dell'orto, Olivier, M, Oakman, Catherine, Dolci, MS, Leo, Angelo Di, Buyse, M, Smoth, Ke-Seay, P. Hainaut, Smoth, KS, Azambuja, ED, Angelo Di Leo, J. Crown, Leo, AD, Dolci, Stella, E. D. Azambuja, Francis, P, Francis, PA, Falagan-Lotsch, Priscila, Marc Buyse, K. Smoth   +71 more
core   +1 more source

Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma

Frontiers in Oncology, 2022
BackgroundAdjuvant chemotherapy has been shown to produce a favorable prognosis for patients with resectable mucosal melanoma (MM), resulting in the need for stratification to optimally select patients to benefit from adjuvant therapy.
Lirui Tang, Xiaoting Wei, Caili Li, Jie Dai, Xue Bai, Lili Mao, Zhihong Chi, Chuanliang Cui, Bin Lian, Bixia Tang, Yu Du, Xuan Wang, Yumei Lai, Xinan Sheng, Xieqiao Yan, Siming Li, Li Zhou, Yan Kong, Zhongwu Li, Lu Si, Jun Guo, Jun Guo   +21 more
doaj   +1 more source

Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer [PDF]

, 2013
Aim: Improving survival for women with early breast cancer (eBC) requires greater attention to the consequences of treatment, including risk to ovarian function. We have assessed whether biochemical markers of the ovarian reserve might improve prediction
Anderson, Richard A., Kelsey, Tom, Rosendahl, Mikkel, Kelsey, Thomas W., Anderson, Richard, Cameron, David A., Cameron, David   +6 more
core   +1 more source

Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial

BMC Cancer, 2018
Background Some patients develop recurrence after curative resection and adjuvant chemotherapy. S-1, an oral fluoropyrimidine, is one of the standard regimens in adjuvant chemotherapy, and is also used in first-line treatment for advanced/metastatic ...
Seiji Ito, Yasuo Ohashi, Mitsuru Sasako
doaj   +1 more source

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy : systematic review and meta-analysis [PDF]

, 2011
Background: Febrile neutropenia (FN) occurs following myelosuppressive chemotherapy and is associated with morbidity, mortality, costs, and chemotherapy reductions and delays.
Akehurst Ron L, Cooper, K. (Katy), Ph. D., Whyte, Sophie, Whyte Sophie, Akehurst, R.L., Madan, Jason, Akehurst, Ron L., Madan, J., Whyte, S., Madan Jason, Katy L Cooper, Cooper, K.L., Jason Madan, Ron L Akehurst, Stevenson Matt D, Sophie Whyte, Stevenson, M. (Matt), Cooper Katy L, Stevenson, M.D., Matt D Stevenson   +19 more
core   +1 more source

Is adjuvant chemotherapy justified in rectal cancer patients after radiochemotherapy and radical resection?

, 2018
Recommendations for the application of post-operative adjuvant chemotherapy in patients who received preope­rative radio-chemotherapy are not consistent.
Bujko, Krzysztof
core   +1 more source